Eicosanoid / Specific receptors
PGE21,2 / EP13; EP24; EP35; EP46,7
PGI28 / IP7,9
PGF2α1 / FP7,150(preferable)
PGD211,1 / DP112;PTGDR2 (also known as CRTH2)7,13
TXA214 / TP7,15
15-deoxyΔ12,14-PGJ216,17 / * but ligand for PPARγ11
LXA418,19 / ALX20
5-HETE21 / *
15-HETE22 / *
LTB4,18,23 / BLT1; BLT224,25
LTC4,LTD4.LTE418,21,26 / CysLTR1; CysLTR227,28
Eoxin C4,D4,E429 / *
*Undefined. Abbreviations: Abbreviations: ALX, lipoxin A4 receptor; BLT, leukotriene B4 receptor; CysLTR, cysteinyl leukotriene receptor; DP1, prostaglandin D2 receptor; EP, prostaglandin E2 receptor; HETE, hydroxyeicosatetraenoic acid; IP, prostacyclin receptor; LT, leukotriene; PG, prostaglandin; PTGDR2prostaglandin D2 receptor 2;TP, thromboxane receptor; TX, thromboxane.
Supplementary references
1.Samuelsson, B., Granstrom, E., Green, K., Hamberg, M. & Hammarstrom, S. Prostaglandins. Ann. Rev. Biochem.44, 669–695(1975).
2.Bergstroem, S., Danielsson, H. & Samuelsson, B. The Enzymatic Formation of Prostaglandin E2 from Arachidonic Acid Prostaglandins and Related Factors 32. Biochim. Biophys. Acta90, 207–210(1964).
3.Funk, C.D.etal. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J.Biol. Chem.268, 26767–26772(1993).
4.Regan, J.W.etal. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol.46, 213–220(1994).
5.Adam, M.etal. Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett.338, 170–174(1994).
6.An, S., Yang, J., Xia, M. & Goetzl, E.J. Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Com.197, 263–270(1993).
7.Narumiya, S., Sugimoto, Y. & Ushikubi, F. Prostanoid receptors: structures, properties, and functions. Physiolog. Rev.79, 1193–1226(1999).
8.Whittaker, N.etal. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins12, 915–928(1976).
9.Boie, Y.etal. Cloning and expression of a cDNA for the human prostanoid IP receptor. J.Biol. Chem.269, 12173–12178(1994).
10.Abramovitz, M.etal. Cloning and expression of a cDNA for the human prostanoid FP receptor. J.Biol. Chem.269, 2632–2636(1994).
11.Nolte, R.T.etal. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature395, 137–143 (1998).
12.Boie, Y., Sawyer, N., Slipetz, D.M., Metters, K.M. & Abramovitz, M. Molecular cloning and characterization of the human prostanoid DP receptor. J.Biol. Chem.270, 18910–18916(1995).
13.Hirai, H.etal. Prostaglandin D2 selectively induces chemotaxis in T helper type2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J.Exp. Med.193, 255–261(2001).
14.Hamberg, M., Svensson, J. & Samuelsson, B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Nat. Acad. Sci. U.S.A.72, 2994–2998(1975).
15.Hirata, M.etal. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature349, 617–620(1991).
16.Fitzpatrick, F.A. & Wynalda, M.A. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed invitro. J.Biol. Chem.258, 11713–11718(1983).
17.Straus, D.S. & Glass, C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev21, 185–210(2001).
18.Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A. & Serhan, C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science237, 1171–1176(1987).
19.Serhan, C.N., Hamberg, M. & Samuelsson, B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl Acad. Sci. USA81, 5335–5339(1984).
20.Fiore, S., Maddox, J.F., Perez, H.D. & Serhan, C.N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J.Exp. Med.180, 253–260(1994).
21.Hammerstrom, S. & Samuelsson, B. Detection of leukotriene A4 as an intermediate in the biosynthesis of leukotrienes C4 and D4. FEBS Lett.122, 83–86(1980).
22.Bailey, J.M., Bryant, R.W., Whiting, J. & Salata, K. Characterization of 11-HETE and 15-HETE, together with prostacyclin, as major products of the cyclooxygenase pathway in cultured rat aorta smooth muscle cells. J.Lipid Res.24, 1419–1428(1983).
23.Samuelsson, B., Borgeat, P., Hammarstrom, S. & Murphy, R.C. Introduction of a nomenclature: leukotrienes. Prostaglandins17, 785–787(1979).
24.Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y. & Shimizu, T. A Gproteincoupled receptor for leukotriene B4 that mediates chemotaxis. Nature387, 620–624(1997).
25.Yokomizo, T., Kato, K., Terawaki, K., Izumi, T. & Shimizu, T. A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J.Exp. Med.192, 421–432(2000).
26.Hammarstrom, S.etal. Structure of leukotriene C. Identification of the amino acid part. Biochem. Biophys. Res. Com.91, 1266–1272(1979).
27.Lynch, K.R.etal. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature399, 789–793(1999).
28.Heise, C.E.etal. Characterization of the human cysteinyl leukotriene 2 receptor. J.Biol. Chem.275, 30531–30536(2000).
29.Feltenmark, S.etal. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15lipoxygenase1 pathway in human eosinophils and mast cells. Proc. Natl Acad. Sci. USA105, 680–685(2008).